Related Experiment Video
Updated: Mar 28, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
MiR-28-3p as a potential plasma marker in diagnosis of pulmonary embolism
Xin Zhou1, Wei Wen2, Xia Shan3
1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, PR China.
Objectives:
Circulating miRNAs have been reported to have potential in detecting various diseases. However, few studies explored differentially expressed miRNAs in plasma of patients with pulmonary embolism (PE). Our study is to identify plasma miRNAs which can serve as potential biomarkers of PE.
Materials And Methods:
Exiqon miRCURY Ready-to-Use PCR Human panel I+II V1.M was conducted to identify differently expressed miRNAs in pooled plasma samples of PE patients compared with normal controls. Expressions of identified miRNAs were assessed in 37 PE patients as well as matched normal individuals followed by validation on six Beagle dogs by quantitative reverse transcription polymerase chain reaction (qRT-PCR).
Results:
Twelve miRNAs were identified from the screening phase. Moreover, miR-134, previously reported related with PE, and hypoxia-induced miR-210 were also submitted to the validation phase. Only miR-28-3p was found significantly elevated in the plasma of PE patients. Compared with the level of plasma miR-28-3p of the dogs before PE, the elevated miR-28-3p did not alter significantly at 1, 2, 4 and 6h after PE. The area under the receiver operating characteristic (ROC) curve of plasma miR-28-3p was 0.792 (95% confidence interval: 0.689-0.896). KEGG pathway analysis showed that miR-28-3p might involve in PE related pathways such as inositol phosphate metabolism and phosphatidylinositol signaling system.
Conclusion:
Our study indicated that elevated plasma miR-28-3p could be used as a non-invasive and stable biomarker in the detection of PE. Further researches on the miRNA are warranted.
Insights
Elevated plasma miR-28-3p shows potential as a non-invasive biomarker for pulmonary embolism (PE) detection. This microRNA (miRNA) was significantly increased in PE patients, aiding in disease diagnosis.
Area of Science:
- Biochemistry
- Molecular Biology
- Genomics
Background:
- Circulating microRNAs (miRNAs) are emerging biomarkers for various diseases.
- Limited research exists on differentially expressed miRNAs in pulmonary embolism (PE) plasma.
- Identifying specific plasma miRNAs can aid in PE diagnosis.
Purpose of the Study:
- To identify plasma miRNAs as potential biomarkers for pulmonary embolism (PE).
- To investigate the diagnostic value of specific miRNAs in PE patients.
Main Methods:
- Screening of differentially expressed miRNAs in pooled plasma from PE patients and controls using Exiqon miRCURY Ready-to-Use PCR.
- Validation of candidate miRNAs in 37 PE patients and matched controls via quantitative reverse transcription polymerase chain reaction (qRT-PCR).
- Animal model validation in Beagle dogs and pathway analysis (KEGG).
Main Results:
- Twelve miRNAs were initially identified; miR-28-3p was significantly elevated in PE patients' plasma.
- Plasma miR-28-3p showed an area under the ROC curve of 0.792, indicating diagnostic potential.
- KEGG analysis suggested miR-28-3p involvement in PE-related pathways like inositol phosphate metabolism.
Conclusions:
- Elevated plasma miR-28-3p serves as a potential non-invasive and stable biomarker for PE detection.
- Further research is warranted to explore the role and application of miR-28-3p in PE.
More Related Videos
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:29Pulmonary Embolism I: Introduction
01:27Pulmonary Embolism III: Nursing Management